The Goldman Sachs Group assumed coverage on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a research note issued to investors on Monday, MarketBeat.com reports. The firm issued a buy rating and a $160.00 target price on the stock.
A number of other research analysts have also commented on KRYS. Citigroup initiated coverage on Krystal Biotech in a report on Thursday, October 12th. They set a buy rating and a $160.00 price target on the stock. Chardan Capital lifted their target price on Krystal Biotech from $148.00 to $153.00 and gave the stock a buy rating in a report on Monday, August 7th. Berenberg Bank initiated coverage on Krystal Biotech in a report on Thursday, September 7th. They set a buy rating and a $154.00 target price on the stock. Cantor Fitzgerald reaffirmed an overweight rating and set a $160.00 target price on shares of Krystal Biotech in a report on Tuesday, November 7th. Finally, HC Wainwright reaffirmed a buy rating and set a $139.00 target price on shares of Krystal Biotech in a report on Monday, August 7th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech currently has an average rating of Buy and a consensus target price of $146.56.
Krystal Biotech Stock Performance
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings results on Monday, November 6th. The company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $3.89. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $6.29 million. Krystal Biotech’s revenue for the quarter was up 8500.0% on a year-over-year basis. During the same period last year, the business posted ($1.17) earnings per share. Analysts forecast that Krystal Biotech will post -3.75 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $127.23, for a total value of $3,180,750.00. Following the transaction, the insider now owns 1,599,206 shares of the company’s stock, valued at approximately $203,466,979.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Krystal Biotech
Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp lifted its holdings in Krystal Biotech by 52.3% in the 1st quarter. State Street Corp now owns 1,068,656 shares of the company’s stock worth $71,108,000 after purchasing an additional 366,855 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in Krystal Biotech by 24.1% in the 1st quarter. Avoro Capital Advisors LLC now owns 1,750,000 shares of the company’s stock worth $140,105,000 after purchasing an additional 340,000 shares during the last quarter. Jennison Associates LLC lifted its holdings in Krystal Biotech by 485.0% in the 3rd quarter. Jennison Associates LLC now owns 340,849 shares of the company’s stock worth $39,538,000 after purchasing an additional 282,583 shares during the last quarter. Fred Alger Management LLC lifted its holdings in Krystal Biotech by 4,608.6% in the 3rd quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after purchasing an additional 163,928 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in Krystal Biotech by 268.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 198,593 shares of the company’s stock worth $23,315,000 after purchasing an additional 144,661 shares during the last quarter. Hedge funds and other institutional investors own 82.30% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.
- Five stocks we like better than Krystal Biotech
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The most upgraded stocks in November have two things in common
- Investing in the High PE Growth Stocks
- Monday.com rocked earnings like it’s the weekend
- How to Invest in Apparel Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.